Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Approves Novartis-Alcon Merger with Conditions -- Update

publication date: Aug 17, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China’s Ministry of Commerce approved the merger between Swiss biopharma Novartis and eye-products company Alcon, though it did require CIBA VISION, a division of Novartis, to terminate its Sales and Distribution Agreement with HaiChang, one of the largest contact lens sellers in China, within the next 12 months. The MoC said Novartis-Alcon together enjoy a 55% stake in the affected markets worldwide and a 60% share in China. More details...

Stock Symbols: (NYSE: NVS) (NYSE: ALC)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...